NuCana PLC
NCNA
View Detailed Chart
3.690USD
-0.300-7.52%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
126.70KMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-7.52%
5 Days
-4.40%
1 Month
+3.65%
6 Months
+336.74%
Year to Date
+210.08%
1 Year
+13.19%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated: 2025-09-19Key Insights
Its valuation is considered fairly valued,and institutional recognition is low. Over the past 30 days, multiple analysts have rated the company as a . The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
0
analysts
--
Current Rating
25.000
Target Price
+2764.34%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-3373, and NUC-7738. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil (5-FU). 5-FU is a prescribed anti-cancer agent. NUC-3373 has been evaluated in a Phase I clinical trial for patients with advanced solid tumors and is under Phase Ib/II clinical trial for patients with advanced colorectal cancer. NUC-7738 is a ProTide transformation of a nucleoside analog, 3’-deoxyadenosine (3’-Da). The Company is evaluating NUC-7738 in a Phase I/II clinical trial for patients with advanced solid tumors. Its pipeline also includes Acelari, which is a ProTide transformation of the nucleoside analog gemcitabine. The Company’s subsidiaries include NuCana, Inc., NuCana Limited and NuCana BioMed Trustee Company Limited.
Overvalued
The company’s latest PE is 0.05, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 554.99K shares, increasing 8.07% quarter-over-quarter.
Held by Baillie Gifford
Star Investor Baillie Gifford holds 0.00 shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.33.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-3373, and NUC-7738. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil (5-FU). 5-FU is a prescribed anti-cancer agent. NUC-3373 has been evaluated in a Phase I clinical trial for patients with advanced solid tumors and is under Phase Ib/II clinical trial for patients with advanced colorectal cancer. NUC-7738 is a ProTide transformation of a nucleoside analog, 3’-deoxyadenosine (3’-Da). The Company is evaluating NUC-7738 in a Phase I/II clinical trial for patients with advanced solid tumors. Its pipeline also includes Acelari, which is a ProTide transformation of the nucleoside analog gemcitabine. The Company’s subsidiaries include NuCana, Inc., NuCana Limited and NuCana BioMed Trustee Company Limited.
Ticker SymbolNCNA
CompanyNuCana PLC
CEO
Websitehttps://www.nucana.com/
Related Instruments
+0.68%
+1.38%
-2.48%
-1.57%
-0.75%
-0.09%
+1.34%
-1.77%
-0.67%
-3.03%
-0.85%
-0.87%
-0.50%
+0.44%
-0.19%
-1.18%
-2.84%
0.00%
+0.30%
-3.72%
